Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study

Reuters

Dec 30, 2025

Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study

Lexaria Bioscience Corp. has released additional results from its Phase 1b clinical study, GLP-1-H24-4, recently completed in Australia. The study evaluated four DehydraTECH™ $(DHT)$ study arms in comparison to the Rybelsus® control arm over a 12-week period. According to the company, secondary efficacy parameters assessed at week 16—such as mean fasting glucose, cholesterol, and LDL cholesterol—showed no statistically significant differences between the DHT arms and the Rybelsus® control. Lexaria stated that the complete study report exceeds 7,000 pages and that additional details are under review. The company also indicated plans for further clinical testing and research in the GLP-1 sector, with updates on development opportunities expected in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1122163) on December 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2595371895"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595371895\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595371895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595371895","market":"fut","top_or_hot":-1,"title":"Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LEXX\">Lexaria Bioscience Corp</a>. has released additional results from its Phase 1b clinical study, GLP-1-H24-4, recently completed in Australia. The study evaluated four DehydraTECH™ <a href=\"https://laohu8.com/S/DHT\">$(DHT)$</a> study arms in comparison to the Rybelsus® control arm over a 12-week period. According to the company, secondary efficacy parameters assessed at week 16—such as mean fasting glucose, cholesterol, and LDL cholesterol—showed no statistically significant differences between the DHT arms and the Rybelsus® control. Lexaria stated that the complete study report exceeds 7,000 pages and that additional details are under review. The company also indicated plans for further clinical testing and research in the GLP-1 sector, with updates on development opportunities expected in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LEXXW\">Lexaria Bioscience Corp</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1122163) on December 30, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-30 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LEXX\">Lexaria Bioscience Corp</a>. has released additional results from its Phase 1b clinical study, GLP-1-H24-4, recently completed in Australia. The study evaluated four DehydraTECH™ <a href=\"https://laohu8.com/S/DHT\">$(DHT)$</a> study arms in comparison to the Rybelsus® control arm over a 12-week period. According to the company, secondary efficacy parameters assessed at week 16—such as mean fasting glucose, cholesterol, and LDL cholesterol—showed no statistically significant differences between the DHT arms and the Rybelsus® control. Lexaria stated that the complete study report exceeds 7,000 pages and that additional details are under review. The company also indicated plans for further clinical testing and research in the GLP-1 sector, with updates on development opportunities expected in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LEXXW\">Lexaria Bioscience Corp</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1122163) on December 30, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LEXX","symbol_name":"Lexaria Bioscience Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDLbj5Tnq:1","article_id":"2595371895","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595371895","pubTimestamp":1767104414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lexaria Bioscience Corp. has released additional results from its Phase 1b clinical study, GLP-1-H24-4, recently completed in Australia. The study evaluated four DehydraTECH  study arms in comparison to the Rybelsus control arm over a 12-week period. According to the company, secondary efficacy parameters assessed at week 16—such as mean fasting glucose, cholesterol, and LDL cholesterol—showed no statistically significant differences between the DHT arms and the Rybelsus control. Lexaria stated that the complete study report exceeds 7,000 pages and that additional details are under review. The company also indicated plans for further clinical testing and research in the GLP-1 sector, with updates on development opportunities expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LEXX":"Lexaria Bioscience Corp","BK4007":"制药"},"translate_title":"Lexaria Bioscience报告1b期GLP-1-H24-4临床研究的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEXX":0.9},"content_text":"Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study\n    \n\nLexaria Bioscience Corp. has released additional results from its Phase 1b clinical study, GLP-1-H24-4, recently completed in Australia. The study evaluated four DehydraTECH™ $(DHT)$ study arms in comparison to the Rybelsus® control arm over a 12-week period. According to the company, secondary efficacy parameters assessed at week 16—such as mean fasting glucose, cholesterol, and LDL cholesterol—showed no statistically significant differences between the DHT arms and the Rybelsus® control. Lexaria stated that the complete study report exceeds 7,000 pages and that additional details are under review. The company also indicated plans for further clinical testing and research in the GLP-1 sector, with updates on development opportunities expected in the future.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1122163) on December 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}